KDM4B and childhood neoplasm: Studies have shown that inhibition of histone lysine demethylase 4B (KDM4B) can delay the growth of tumor cells and inhibit the core transcription factor PAX3‐FOXO1, suggesting that KDM4B may be a potential therapeutic target for malignant childhood tumors such as PAX‐FOXO1+ RMS [45].